Abatacept Biosimilar

Additional Information:
Abatacept (trade name Orenc Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation. || Abatacept Biosimilar Recombinant protein composed of the extracellular domain of CTLA-4 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1). Source: The abatacept biosimilar protein was produced in the Orenc biosimilar CHO stable cell line. Specificity/Sensitivity: The abatacept biosimilar protein specifically binds to the human CD80 (B7-1) with more avidity than to CD86 (B7-2). Applications: Functional assays, and those assays for studying biological |0.2 uM filtered solution, pH 6.8 to 7.4, no stabilizers or preservatives. Endotoxin: Purity: >95% by SDS-|The abatacept biosimilar protein is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. Syd Labs also provides the following CTLA-4 Fc Fusion Protein biosimilar: Belatacept Biosimilar Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars: Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody